

1 Pathogenic accumulation of T follicular helper cells in lupus disease depends on
2 PD-L1 and IL-4 expressing basophils.

3
4
5
6

7 **Authors:** John TCHEN ^{1,2}, Quentin SIMON ^{1,2}, Léa CHAPART ^{1,2}, Yasmine LAMRI ^{1,2}, Fanny SAIDOUNE ^{1,2},
8 Emeline PACREAU ^{1,2}, Christophe PELLEFIGUES ^{1,2}, Julie BEX-COUDRAT ^{1,2}, Hajime KARASUYAMA ³,
9 Kensuke MIYAKE ³, Juan HIDALGO ⁴, Padraic G. FALLON ⁵, Thomas PAPO ^{1,2,7}, Ulrich BLANK ^{1,2}, Marc
10 BENHAMOU ^{1,2}, Guillaume HANOUNA ^{1,2,6}, Karim SACRE ^{1,2,7}, Eric DAUGAS ^{1,2,6} and Nicolas CHARLES ^{1,2}

11 **Affiliations:**

12 1- Université Paris Cité, Centre de Recherche sur l'Inflammation, INSERM UMR1149, CNRS EMR8252,
13 Faculté de Médecine site Bichat, 75018, Paris, France

14 2- Université Paris Cité, Laboratoire d'Excellence Inflamex, 75018, Paris, France

15 3- Inflammation, Infection and Immunity Laboratory, TMDU Advanced Research Institute, Tokyo
16 Medical and Dental University (TMDU), Tokyo, Japan

17 4- Universidad Autonoma de Barcelona, Facultad de Biociencias, Unidad de Fisiologia Animal
18 Bellaterra, Bellaterra Campus 08193, Barcelona, Spain

19 5- School of Medicine, Trinity College Dublin, Dublin 2, Ireland.

20 6- Service de Néphrologie, Hôpital Bichat, Assistance Publique – Hôpitaux de Paris, 75018, Paris,
21 France

22 7- Service de Médecine Interne, Hôpital Bichat, Assistance Publique – Hôpitaux de Paris, 75018, Paris,
23 France

24

25 ***Correspondence:**

26 Nicolas Charles, PhD

27 Centre de Recherche sur l'Inflammation, INSERM UMR1149, CNRS ERL8252,

28 Université Paris Cité, Faculté de Médecine site Bichat,

29 16 rue Henri Huchard, 75018 Paris, France.

30 Phone: +33 157277306

31 E-mail: nicolas.charles@inserm.fr

32 ORCID : [0000-0002-5416-5834](https://orcid.org/0000-0002-5416-5834)

33 **NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

34 ABSTRACT

35 Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by autoantibodies
36 raised against nuclear antigens and whose production is promoted by autoreactive T follicular helper
37 (TFH) cells. Basophils, by accumulating in secondary lymphoid organs (SLO), amplify autoantibody
38 production and disease progression through mechanisms to be defined. Here, we demonstrate that a
39 functional relationship between TFH cells and basophils occurs in SLO during lupus pathogenesis. On
40 SLE patient blood basophils, PD-L1 expression was upregulated and associated with TFH and TFH2
41 cell expansions and with disease activity. In two distinct lupus-like mouse models, TFH cell
42 pathogenic accumulation, maintenance and function, and disease activity were dependent on
43 basophils and their expressions of PD-L1 and IL-4. Our study establishes a direct link between
44 basophils and TFH cells in the SLE context that promotes autoreactive IgG production and lupus
45 nephritis pathogenesis. Altering the basophil/TFH cell axis in the SLE context may represent a
46 promising innovative intervention strategy in SLE.

47

48 KEYWORDS:

49 Basophils, T follicular helper cells, autoantibodies, PD-L1, IL-4, Systemic Lupus Erythematosus, lupus
50 nephritis, pathophysiology, pristane, CT-M8.

51

52

53 INTRODUCTION

54 Systemic lupus erythematosus (SLE) is a multifactorial autoimmune disease that can affect different
55 organs including joints, skin, or kidneys (lupus nephritis). A break in tolerance to nuclear self-antigens
56 leads to an accumulation of autoreactive B and T cells in SLE patients that drives the production of
57 autoreactive antibodies mainly raised against nuclear antigens, such as double-stranded DNA
58 (dsDNA) or ribonucleoproteins (RNP). These autoantibodies form circulating immune complexes (CIC)
59 after aggregation to complement factors and autoantigens. CIC deposit in target organs where they
60 can induce a chronic inflammation leading to tissue damage and organ dysfunction. In parallel, CIC
61 activate innate immune cells such as plasmacytoid dendritic cells, monocytes/macrophages,
62 neutrophils, and basophils that enhance autoantibody production through the release of various
63 inflammatory mediators and initiate a deleterious amplification loop of the disease^{1,2}.

64 Autoantibody production is a key event in lupus pathogenesis. Its disruption represents an intensive
65 area of clinical development of biotherapies targeting directly the B cells or pathways promoting
66 their survival and maturation³. Recent advances in the understanding of SLE pathogenesis have shed
67 some light on the role of T follicular helper CD4⁺ (TFH) cells. TFH cells are central for follicular B cell
68 maturation into antibody-secreting cells and their numbers and functions are dysregulated in both
69 human SLE patients and some lupus-like murine models⁴⁻⁸. TFH cells are characterized by their
70 expression of the transcription factor BCL6 and their surface expression of C-X-C motif chemokine
71 receptor 5 (CXCR5) which allows their localization into the germinal centers to provide B cell help
72 through IL-21 production and promote the maturation of antibody-secreting cells⁷. TFH cells express
73 programmed cell-death 1 receptor (PD-1) that is essential for their positioning, functions, and
74 regulation in secondary lymphoid organs (SLO)⁹. GATA-3 transcription factor expression, IL-4
75 production, and potent help provided to B cells characterize the TFH type 2 (TFH2) cell subset that is
76 overrepresented in the lupus context and associated with disease activity⁶.

77 Basophils are activated during SLE pathogenesis and accumulate in SLO where they promote
78 autoantibody production by supporting antibody-secreting plasmablast accumulation^{10,11}. Depleting
79 basophils in lupus-like mouse models with established disease dampens lupus-like activity by
80 reducing plasmablast numbers, autoantibody titers, CIC deposits in glomeruli, and kidney
81 inflammation^{10,11}, thus demonstrating that basophils are responsible for an amplification loop driving
82 the disease to a pathogenic threshold. In agreement, constitutive basophil deficiency prevents lupus-
83 like disease onset in the pristane-induced lupus-like disease model¹². In this context, targeting the
84 addressing of basophils to SLO has demonstrated promising therapeutic potential^{11,13}. In the *Lyn*^{-/-}
85 lupus-like mouse model, we previously showed that basophils accumulate in SLO where they express
86 surface molecules that suggest interactions with the B and T cell compartments to promote plasma
87 cell maturation and antibody secretion¹⁰. However, the mechanisms by which basophils, once in SLO,
88 actually promote this disease amplification loop remains unknown.

89 Here, we screened cell surface molecules on blood basophils from SLE patients that could support a
90 functional interaction of these cells with SLO cell partners in the lupus context. We demonstrate *in*
91 *vitro* in humans and *in vivo* in two different SLE mouse models that PD-L1 expression and IL-4
92 production by basophils are required to promote the cross-talk of these cells with TFH cells to sustain
93 TFH cell pathogenic accumulation, TFH2 cell differentiation, and thereby mediate SLE disease onset
94 and progression.

95 **RESULTS**

96 **Human blood basophils from SLE patients overexpress PD-L1**

97 TFH, and especially TFH2, cells are significant contributors to the pathophysiology of SLE. Proportions
98 among CD4⁺ T cells of circulating TFH (cTFH) and cTFH2 cells are increased in several SLE patient
99 cohorts and lupus-like mouse models^{4-7,14,15}. We first assessed these cTFH cells (CD3⁺ CD4⁺ CXCR5⁺
100 ICOS⁺ PD-1⁺ cells) and cTFH2 cells (CCR6⁻ CXCR3⁻ TFH cells) in our SLE patient cohort (**Table S1**) and
101 confirmed both their increased representation among CD4⁺ T cells and a cTFH2 cell bias that was
102 associated with disease activity (**Fig. 1a-c**).

103 We and others reported that peripheral basopenia and activation of blood basophils correlate with
104 disease activity in SLE patients^{10,11,16}. Our current SLE patient cohort further confirmed this blood
105 basophil phenotype as evidenced by basopenia and overexpression of the activation marker CD203c,
106 the chemokine receptor CXCR4, and the L-selectin CD62L, all of them being associated with disease
107 activity (**Fig. S1a-e** and **Fig. 1d**).

108 To investigate whether, in the SLE context, human basophils were more prone to interact with TFH
109 cells, we assessed the expression levels of several surface markers identified to be relevant
110 interacting molecules with TFH cells. PD-L2, ICOSL, and OX40L were barely detected on the surface of
111 human blood basophils and no difference in their expression levels on basophils from healthy donors
112 or SLE patients was observed (**Table S2**). Nevertheless, PD-L1 was strongly upregulated on the
113 surface of SLE patient blood basophils as compared to healthy donor blood basophils, independently
114 of the activity of the disease (**Fig. 1e** and **Table S2**). In addition, PD-L1 expression on SLE patient
115 blood basophils correlated with the basophil activation status (Spearman $r=0.3113$, $P < 0.0001$,
116 $n=204$) (**Fig. S1f**). CD84, a member of the SLAM family of proteins important for TFH cell regulation¹⁷,
117 was highly expressed by human basophils (**Fig. S1g** and **Table S2**). Although no significant increase in
118 CD84 expression on blood basophils from the whole SLE patient cohort was found, its expression was

119 significantly increased on blood basophils from active SLE patients as compared to healthy volunteers
120 (**Fig. S1g** and **Table S2**).

121 Altogether, these results demonstrated that basophils from SLE patients overexpress PD-L1 and
122 CD84, suggesting that a basophil-TFH cell interaction may occur during lupus pathogenesis.

123 **Basophil-TFH cell axis in lupus-like mouse models**

124 We next sought to verify whether this increased expression of PD-L1 on basophils from SLE patients
125 was also detected on basophils from lupus-like mouse models in which basophil contribution to
126 disease activity is established^{10,11,18}. PD-L1 expression was increased on the surface of basophils from
127 both pristane-induced and *Lyn*^{-/-} lupus-like mouse models in the analyzed compartments (blood,
128 spleen, and lymph nodes) (**Fig. 2a,b**). As shown in other human studies and previous reports^{7,11},
129 increased TFH cell proportions among CD4⁺ T cells and basophil accumulation were observed in both
130 lupus-like mouse models in blood and the secondary lymphoid organs spleen, and lymph nodes (**Fig.**
131 **2c-f** and **Fig. S2**). These results suggest a positive correlation between basophils and TFH cells during
132 lupus-like disease.

133 To evaluate whether a functional relationship between basophils and TFH cells was taking place
134 during the course of the disease, we depleted basophils through diphtheria toxin injection in
135 *Mcpt8*^{DTR} mice in both lupus-like models during ten days before their analysis (**Fig. S2a,b**). We
136 previously showed that basophil depletion dampens CD19⁺CD138⁺ short-lived plasma cell numbers in
137 SLO, autoantibody titers, kidney deposits and inflammation, and disease activity in these
138 models^{10,11,18}. Here, in agreement, efficient DT-mediated basophil depletion (**Fig. 2e,f** and **Fig. S2a,b**)
139 resulted in a dramatic decrease in autoreactive IgG antibody titers in both pristane-induced and *Lyn*^{-/-}
140 ^{-/-} lupus-like mouse models (**Fig. 2g,h**). In addition, it abrogated the increase in TFH cell proportions in
141 blood and SLO from lupus-like mice (**Fig. 2c,d** and **Fig. S2c,d**), strongly suggesting a functional
142 relationship between the two cell compartments. Of note, basophil depletion in *Lyn*^{-/-} *Mcpt8*^{DTR} mice

143 did not modify the proportion of regulatory TFH (TFR) cells among the TFH cell population (**Fig.**
144 **S3a,b**).

145 We recently showed that basophils play a nonredundant role in pristane-induced lupus-like disease
146 and that basophil-deficient mice (*Mcpt8^{CT/+} Rosa26^{DTA/+}* mice) are resistant to pristane-induced lupus-
147 like disease onset¹². The functional relationship between basophils and TFH cells was further
148 confirmed in this mouse model since no increase in the TFH cell proportion was observed in pristane-
149 injected basophil-deficient mice as compared to control mice (*Mcpt8^{CT/CT} Rosa26^{+/+}*) in any of the
150 analyzed compartments (**Fig. 2i**).

151 The functional interaction between the two cell types seemed restricted to the lupus-like
152 environment. Indeed, basophil depletion in WT animals in both models or constitutive basophil
153 deficiency did not modify the basal proportions of TFH cells in the observed compartments (**Fig.**
154 **2c,d,i**). Moreover, basophils, which are not involved in the humoral response to the ovalbumin (OVA)
155 protein after intraperitoneal immunization in alum¹⁹, did not influence the rise in TFH cell numbers in
156 these conditions. Indeed, we could measure the induction of TFH cells in OVA-immunized mice which
157 was associated with the production of anti-OVA IgG antibodies but not with the accumulation of
158 basophils in the spleen nor in the draining (mesenteric) lymph node (**Fig. S3c-f**). DT-mediated
159 basophil depletion starting the last 48 hours of the immunization procedure did not modify the TFH
160 cell response nor the anti-OVA IgG titers in immunized mice, suggesting that basophils were not
161 involved in the support of TFH cells in a protein-immunization setting, unlike what we observed in
162 the lupus-like context (**Fig. S3c-f** and **Fig. 2**).

163 Altogether, these data strongly suggest that basophils, by accumulating in SLO, enable the expansion
164 of the TFH cell population in two distinct lupus-like mouse models and that basophils and TFH cells
165 may share a functional relationship in the lupus-like context.

166 **Basophils control TFH cell ability to produce IL-21 and IL-4 in a lupus-like context**

167 We next assessed whether basophils could influence the cytokine production abilities of the
168 expanded TFH cells during the disease. First, the proportions of spleen TFH cells producing IL-21
169 without any restimulation were significantly increased in both lupus-like models and further
170 amplified after phorbol myristate acetate (PMA) and ionomycin restimulation as compared to spleen
171 TFH cells from control mice (**Fig. 3a-c**). This suggested that in the lupus-like context, TFH cells are
172 more prone to provide IL-21 to surrounding cells in these mouse models. Second, the same
173 observations were done concerning IL-4 production by TFH cells showing a TFH2 bias in these two
174 lupus-like models (**Fig. 3d-f**), as was also observed in the SLE patient cohort (**Fig. 1c**). Of note, no such
175 bias was observed for IFN γ production by TFH cells in any of the mouse models (**Fig. 3g,h**). Third,
176 basophil depletion dramatically dampened both constitutive and PMA-ionomycin-induced IL-21 and
177 IL-4 productions by TFH cells only in the lupus-like context, without significantly influencing their IFN γ
178 production ability (**Fig. 3a-h**). These results strongly suggest that, in the lupus-like context, basophils
179 promoted TFH cell-derived IL-21 and IL-4 production ability and were responsible for a TFH2 cell bias
180 of this T cell population.

181 Both IL-6 and IL-4 are involved, respectively, in TFH and TFH2 cell differentiation^{7,15}. Basophils are
182 potent producers of these cytokines^{20,21}. We next assessed whether basophils in both pristane-
183 injected and Lyn-deficient animals were more prone to produce these cytokines with or without
184 PMA-ionomycin restimulation. Unlike what was observed in basophils from control mice, constitutive
185 IL-4 and IL-6 productions were significantly detected in non-restimulated basophils from both lupus-
186 like models, whereas no major differences were noticed after PMA-ionomycin restimulation (**Fig. 3i-**
187 **m**). These results suggested that during the course of the disease, along with their increased
188 expression of PD-L1 (**Fig. 2a,b**), basophils produce IL-6 and IL-4 *in vivo* which may explain some of
189 their effects on the expansion of the TFH cell population and its TFH2 cell bias.

190 **Basophils promote *ex vivo* TFH cell differentiation through IL-4- and PD-L1-dependent mechanisms**

191 Next, we evaluated the effects of basophils and basophil-expressed mediators on the differentiation
192 of TFH cells *ex vivo* in a co-culture system. The presence of basophils induced a clear differentiation
193 of the CD3/CD28-activated naïve CD4⁺ T cells towards the TFH cell subset with an increased ability of
194 these TFH cells to produce IL-21 and IL-6 (**Fig. 4a-c**). Moreover, the basophil-induced TFH cell
195 differentiation was biased towards the TFH2 cell subset as evidenced by an increased ability to
196 produce IL-4 and IL-13 (**Fig. 4d,e**). We next bred CT-M8 (or *Mcpt8^{CT/CT}*) mice¹² with *Il4^{fl/fl}*²², *Il6^{fl/fl}*²³, or
197 *Pdl1^{fl/fl}*²⁴ mice and generated mice deficient for IL-4, IL-6, or PD-L1 selectively in the basophil
198 compartment (**Fig. S4a-c**). IL-4-deficient basophils could not induce any of the effects on the TFH cell
199 differentiation as compared to WT basophils (**Fig. 4a-e**). IL-6-deficient basophils could still induce TFH
200 cell differentiation despite reduced IL-6, but increased IL-21, production by TFH cells (**Fig. 4a-c**) and
201 had a limited effect on the TFH2 cell differentiation (**Fig. 4d,e**). Interestingly, PD-L1 expression by
202 basophils was mandatory to induce TFH cell differentiation but had a limited impact on the TFH2 cell
203 differentiation that was completely dependent on basophil-expressed IL-4 (**Fig. 4a-e**). Of note, PMA-
204 ionomycin restimulation of the co-cultured cells in the aforementioned conditions led to the same
205 conclusions (**Fig. S4d-g**).

206 Altogether, these results demonstrated that basophils induce *ex vivo* TFH cell differentiation in an IL-
207 4- and PD-L1-dependent manner and that basophil-derived IL-6 is dispensable for these effects.

208 **CD4⁺ T cells promote basophil ability to induce TFH cell differentiation *ex vivo***

209 In parallel, we analyzed the effects of the CD4⁺ T cells on the basophil compartment. The presence of
210 CD4⁺ T cells up-regulated PD-L1 expression on basophils and induced constitutive IL-4, IL-6, and IL-13
211 productions by these cells (**Fig. 4f-k**). The CD4⁺ T cell-induced up-regulation of PD-L1 on basophils
212 was partially dependent on the IL-4 produced by basophils themselves, but independent of basophil-
213 derived IL-6 (**Fig. 4f,g**). Conversely, the CD4⁺ T cell-induced IL-4 (and IL-6) production by basophils
214 was partially dependent on PD-L1 expressed by basophils without impacting their maximal
215 production ability (**Fig. 4h-i**, and **Fig. S4h,i**). IL-6 deficiency in basophils did not alter their ability to

216 produce IL-4 constitutively in the presence of CD4⁺ T cells nor after PMA-ionomycin restimulation but
217 enhanced their IL-13 production only in the former situation (**Fig. 4h-k** and **Fig. S4h-j**). These results
218 suggest that PD-L1 engagement on basophils by CD4⁺ T cells, beyond promoting IL-21 production by
219 TFH cells (**Fig. 4b**), was responsible for the extent of T cell-induced cytokine production by basophils.
220 This may explain why PD-L1 deficient basophils could not promote TFH cell differentiation (**Fig. 4a**).
221 Of note, CD4⁺ T cells induced IL-13 production by basophils and enhanced their maximal ability to
222 produce this cytokine independently of their IL-4 or PD-L1 expression (**Fig. 4k** and **Fig. S4j**).

223 Altogether, these results strongly suggest that a bi-directional interaction between naïve CD4⁺ T cells
224 and basophils leads to the differentiation of TFH cells via a mechanism mainly depending on IL-4 and
225 PD-L1 expression by basophils but independent of the basophil-derived IL-6.

226 **PD-L1 controls the basophil-TFH cell functional relationship during lupus-like disease**

227 We next sought to validate *in vivo* the relevance of PD-L1 expression by basophils in their functional
228 relationship with TFH cells in the lupus-like context. Pristane injection did not lead to TFH cell
229 accumulation in SLO in mice with basophil-restricted PD-L1-deficiency (*Mcpt8^{CT/+} Pdl1^{f/f}*) as
230 compared to WT animals (*Mcpt8^{CT/+}*) (**Fig. 5a** and **Fig. S5**). However, PD-L1 expression by basophils
231 was not required for basophil accumulation in SLO (**Fig. 5b**). Both the lupus-like context *in vivo* (**Fig.**
232 **3l,m**) and the co-culture system *in vitro* (**Fig. 4h-k**) induced IL-4 and IL-6 production by basophils.
233 Here, PD-L1 deficiency on basophils completely prevented these cytokine basal productions in the
234 lupus-like context (**Fig. 5c,d**). This was associated with a non-expansion of CD19⁺CD138⁺ cells in SLO
235 (**Fig. 5e**) leading to dramatically reduced anti-RNP autoreactive IgG titers in the blood (**Fig. 5f**).
236 Moreover, increased IgG and C3 glomerular deposits were barely detectable in the kidney of
237 pristane-injected *Mcpt8^{CT/+} Pdl1^{f/f}* mice as compared to their WT counterparts (**Fig. 5g,h**).

238 Altogether, these results strongly suggest that PD-L1 basophil expression and up-regulation during
239 lupus development were not involved in basophil accumulation in SLO but were responsible for the

240 basophil-induced promotion of TFH and short-lived plasma cell expansions and subsequent
241 pathological parameters.

242 **Basophil-derived IL-4 exerts a dual effect during lupus-like disease development**

243 Since TFH cell differentiation *ex vivo* depended on IL-4 expression by basophils (**Fig. 4**), we next
244 sought to verify whether basophil-derived IL-4 was mandatory for the basophil-TFH cell functional
245 relationship in the lupus-like context. As suggested above, IL-4 deficiency selectively in the basophil
246 compartment (*Mcpt8^{CT/+} Il4^{fl/fl}*) prevented the pristane-induced TFH cell accumulation in SLO as
247 compared to WT (*Mcpt8^{CT/+}*) animals (**Fig. 6a**). By contrast, basophil recruitment into SLO upon
248 pristane treatment of the mice was not dependent on basophil-derived IL-4 since basophil
249 accumulation in these locations in mice was similar in *Mcpt8^{CT/+} Il4^{fl/fl}* and *Mcpt8^{CT/+}* WT animals (**Fig.**
250 **6b**). Surprisingly, CD19⁺CD138⁺ cells still accumulated in SLO despite selective basophil IL-4 deficiency
251 (**Fig. 6c**). This phenotype was associated with a still significant constitutive IL-6 production by IL-4-
252 deficient basophils in the lupus-like context (**Fig. 6d**). However, no significant titers of anti-RNP IgG
253 autoantibodies were detected in the blood of pristane-injected *Mcpt8^{CT/+} Il4^{fl/fl}* mice as compared to
254 their WT counterparts. In line with this feature, no IgG deposits were present in the glomeruli of
255 pristane-treated mice with basophil-specific IL-4 deficiency but C3 deposits, although reduced, were
256 still detected (**Fig. 6f** and **Fig. S6a,b**). Along with the accumulation of CD19⁺CD138⁺ cells in the SLO,
257 the latter result led us to assess the presence of autoreactive IgM in the pristane-treated *Mcpt8^{CT/+}*
258 *Il4^{fl/fl}* mice. As suspected, increased titers of anti-RNP IgM in the plasma of mice with IL-4 deficient
259 basophils were observed as compared to pristane-treated *Mcpt8^{CT/+}* WT mice (**Fig. 6g**). These
260 autoreactive IgM were not detected in the blood from pristane-injected basophil-specific PD-L1-
261 deficient mice nor constitutive basophil-deficient mice (**Fig. 6g**) in line with the absence of
262 plasmablast accumulation in SLO from these mice (**Fig. 5e** and ¹²). These anti-RNP IgM titers
263 correlated with the presence of IgM deposits in the glomeruli of the corresponding mice (**Fig. 6h,i**).

264 Altogether, these results strongly suggest that TFH cell pathogenic accumulation in SLO and
265 autoreactive IgG titers induced by pristane were dependent on the basophil-derived IL-4. However,
266 CD19⁺CD138⁺ short-lived plasma cell accumulation, which is dependent on basophils (**Fig. 2** and
267 ^{11,12,18}), was not dependent on IL-4 production by basophils. This led to an accumulation of plasmatic
268 autoreactive anti-RNP IgM, with no IgG deposits but increased C3 deposits in glomeruli of the
269 *Mcpt8^{CT/+} Il4^{fl/fl}* mice, suggesting that basophil-derived IL-4 was both enabling autoreactive antibody
270 switch towards the IgG isotype and TFH cell accumulation that promoted this phenomenon as
271 well^{7,15}.

272 **Human basophils drive *ex vivo* TFH cell and TFH2 cell differentiation through IL-4, IL-6, and PD-1-** 273 **dependent mechanisms**

274 We next sought to validate the ability of basophils to promote TFH cell differentiation in a human co-
275 culture system. First, CD3- and CD28-activated human naïve CD4⁺ T cells were cultured for three days
276 without or with increasing numbers of purified human basophils demonstrating the capacity of
277 human blood basophils to induce TFH cell differentiation (**Fig. 7a-c**) more potently than mouse
278 spleen basophils (**Fig. 4a**). Next, cultures of CD3- and CD28-activated human naïve CD4⁺ T cells alone
279 or together with basophils were repeated in the presence of blocking antibodies targeting IL-4, IL-6,
280 PD-1, or their corresponding isotype controls. As seen in the murine system, IL-4 and PD-1
281 antagonisms led to a dramatic decrease in the ability of human basophils to drive CD4⁺ T cell
282 differentiation into TFH cells (**Fig. 7d**). IL-6 blockade also decreased basophil-induced TFH cell
283 differentiation, probably due to its effects on the T cell-derived IL-6 (**Fig. 7d**). Most of the basophil-
284 induced TFH cells were belonging to the TFH2 cell subset expressing neither CCR6 nor CXCR3 (**Fig.**
285 **7e,f**). This TFH2 cell subset differentiation was dramatically dampened by the blockade of IL-4, IL-6,
286 or PD-1 (**Fig. 7e,f**).

287 Altogether, these data demonstrate that human basophils could induce human naïve CD4⁺ T cell
288 differentiation into TFH cells, especially into the TFH2 cell subset, and that this was dependent on IL-

289 4 and PD-1. Together with the PD-L1 overexpression by blood basophils from SLE patients (**Fig. 1e**),
290 these results strongly suggest that, as demonstrated in the lupus-like mouse models (**Figs. 2-6**),
291 basophils promote the pathogenic accumulation of TFH cells during SLE pathogenesis through their
292 expression of PD-L1 and IL-4.

293 **DISCUSSION**

294 In this study, we have identified mechanisms by which basophils control the pathogenic
295 accumulation of TFH cells in SLO to promote autoreactive IgG production during SLE pathogenesis.

296 In a normal antigen-driven immunization process, germinal centers (GC) are key structures that allow
297 B cell maturation into high affinity and class-switched antibody-secreting cells²⁵. The formation and
298 maintenance of these structures depend on TFH cells⁷. Basophils are dispensable to mount an
299 efficient humoral response to OVA protein immunization¹⁹ and do not control basal TFH or OVA-
300 induced TFH cell populations (this study). Importantly, in the latter conditions, basophils do not
301 accumulate in SLO in contrast to the lupus-like context. Dysregulated expansion of TFH cells in an
302 SLE-like context occurs through spontaneous GC-like reactions which are favored by the abnormal
303 cytokine milieu and mainly in the extrafollicular (EF) area⁷. Our results indicate that the pathogenic
304 accumulation of TFH cells in SLO in a lupus-like context, and thus spontaneous TFH cell responses, are
305 fully dependent on SLO-localized basophils and more precisely mediated by basophil expression of
306 PD-L1 and IL-4.

307 The impairment of this basophil-dependent pathogenic accumulation of TFH cell in SLO led to a
308 dramatic reduction in autoreactive anti-RNP IgG production and IgG kidney deposits, further
309 validating the relevance of both cell types in autoantibody and pathogenic CIC productions in a lupus-
310 like context. Investigating whether basophils control spontaneous EF TFH cell responses in other
311 autoimmune diseases such as rheumatoid arthritis or multiple sclerosis may lead to developing
312 common therapeutic strategies for these different autoimmune conditions that may share some
313 pathophysiological pathways²⁶.

314 Recently, Kim *et al.* showed that TFH2 cells are induced by, and produce some, IL-4. These TFH2 cells
315 are central in humoral autoimmunity, promote autoreactive IgE production with their frequencies
316 increased in both SLE patients and also some SLE-like mouse models¹⁵. Accordingly, systemic IL-4
317 blockade dampened TFH2 cell accumulation and their deleterious effects in the *Ets1^{ΔCD4}* lupus-like

318 mouse model. As exogenous IL-4 induces Gata3 expression in T cells enabling TH2 cell
319 differentiation²⁷, exogenous IL-4 enabled Gata3⁺ TFH2 cell accumulation in an SLE-like context in a
320 similar way¹⁵. Our data strongly suggest that basophils deliver the required IL-4-induced priming to
321 CD4⁺ T cells in a PD-L1-dependent manner that allows TFH and TFH2 cell accumulation in the lupus-
322 like context. Further studies will be required to validate this feature in other lupus-like mouse models
323 including *Ets1*^{ΔCD4} mice. This IL-4 mediated basophil-TFH pathogenic axis is important since basophil
324 depletion may represent a safer therapeutic strategy than global IL-4 neutralization. Indeed, this
325 cytokine controls a large number of physiologically protective processes^{28,29} and other deleterious
326 pathways involved in SLE pathophysiology may limit the benefits for the patients of long-term IL-4
327 blockade².

328 Both human and murine basophils promoted CD3/CD28 activated naïve CD4⁺ T cell differentiation
329 into TFH cells *ex vivo* in the absence of specific antigen or recognized potent antigen-presenting cells.
330 These effects depended on basophil-expressed IL-4 and PD-L1 (but not on IL-6) for murine cells and
331 were dampened by IL-4, IL-6, or PD-1 blocking antibodies for human cells. This setting may resume
332 spontaneous TFH cell responses occurring in the SLE context⁷. TCR repertoire analysis of these
333 basophil-induced TFH cells may help to decipher whether these spontaneous TFH cell responses
334 favor autoreactivity of the TFH cell compartment.

335 pDC and type I IFN have recently been shown to promote EF T-dependent B cell responses to
336 extracellular self DNA³⁰. Our data suggest that basophils and their PD-L1 expression are mandatory to
337 induce TFH cell pathogenic accumulation and B cell response to nuclear antigens. PD-L1 expression
338 by CD11c-expressing cells inhibits TFH cell response in experimental autoimmune
339 encephalomyelitis³¹. Type I IFN promotes human basophil apoptosis, but this effect is rescued by IL-
340 3³² whose production (mainly by T cells³³) is increased during SLE pathogenesis^{34,35} and acts as well
341 on pDC survival³⁶. Thus, it may be relevant to study the interplay between basophils and DC subsets
342 in this process. pDC or follicular DC and basophils may indeed compete to engage PD-1 on TFH cells

343 to respectively inhibit or promote TFH cell expansion and TFH2 cell differentiation in EF responses in
344 an autoimmune context.

345 PD-L1 expression by basophils is known in humans and may be induced by IFN γ ³⁷. PD-L1 upregulation
346 on human basophils has recently been described during SARS-CoV2 infections³⁸ although it is not
347 directly induced by the virus³⁹. Interestingly, basopenia occurs in acute SARS-CoV2 infection
348 suggesting putative recruitment of basophils to SLO⁴⁰. This hypothesis is further supported by
349 basophil overexpression of CXCR4 and CD62L in the SARS-CoV-2 infection setting, similar to what we
350 described in SLE patients^{10,11,40,41}. Normalization of both blood basophil numbers and activation
351 markers is associated with the humoral response and recovery of COVID-19 patients^{40,42}. This may
352 indicate a role for PD-L1-overexpressing basophils in TFH cell induction to promote antiviral humoral
353 response. EF responses occurring in lupus-prone mice and during some infections can quickly
354 involute if new plasmablasts are not generated²⁵. Thus, controlling basophil function or localization in
355 SLO during viral infections may represent interesting therapeutic strategies to promote or sustain the
356 antiviral humoral response.

357 Unexpectedly, when injected with pristane, mice with IL-4-deficient basophils still showed some
358 plasmablast accumulation in SLO and C3 kidney deposits despite the absence of TFH cell
359 accumulation, anti-RNP IgG induction, and IgG kidney deposits. Unlike pristane-injected basophil-
360 deficient mice or mice with PD-L1-deficient basophils, *Mcpt8^{CT/+}IL4^{fl/fl}* mice developed high titers of
361 anti-RNP IgM. This indicates that basophils express factors other than IL-4 in SLO during lupus-like
362 disease responsible for their PD-L1-dependent action on B cell maturation into plasmablast in the
363 absence of TFH cell pathogenic accumulation. However, it strongly suggests as well that basophil-
364 derived IL-4 is mandatory for autoantibody class switch towards IgG in the lupus-like context. Further
365 characterization of this B cell–basophil relationship in SLO in the SLE context will be required to
366 identify basophil-derived factors that contribute to TFH-independent plasmablast proliferation.

367 Our study establishes a direct link between basophils and TFH cells in the SLE context that promotes
368 autoreactive IgG production and lupus nephritis pathogenesis. Altering the basophil/TFH cell axis in
369 the SLE context may represent a promising innovative intervention strategy in SLE.

370

371 **Acknowledgments**

372 This work was supported by the Fondation pour la Recherche Médicale (FRM) [grant #
373 EQU201903007794] to N.C., the French Agence Nationale de la Recherche (ANR) [grants # ANR-19-
374 CE17-0029 BALUMET to N.C. and ANRPIA-10-LABX-0017 INFLAMEX], the Ministerio de Economía y
375 Competitividad y Fondo Europeo de Desarrollo Regional (RTI2018-101105-B-I00) to J.H., by the
376 Centre National de la Recherche Scientifique (CNRS), by Université Paris-Cité and by the Institut
377 National de la Santé et de la Recherche Médicale (INSERM). We acknowledge the expert work from
378 the members of the animal core facility (I. Renault and S. Olivré), the flow cytometry core facility (G.
379 Gautier, J. Da Silva and V. Gratio) and the imaging facility (S. Benadda) of the Centre de Recherche
380 sur l'Inflammation (INSERM UMR1149), and the help from O. Thibaudeau and L. Wingertsmann from
381 the morphology core facility (INSERM UMR1152).

382 **Authors' contributions**

383 J.T. designed experiments, conducted experiments, and wrote the manuscript. N.C. conceived the
384 project, designed experiments, conducted experiments, wrote the manuscript, and directed the
385 project. Q.S., L.C., Y.L., F.S., E.P., J.B-C, C.P., U.B., M.B., G.H., K.S., and E.D. conducted experiments,
386 analyzed the data, and/or edited the manuscript. H.K. and K.M. provided the *Il4^{fl/fl}* and *Mcpt8^{DTR}* mice
387 and edited the manuscript. J.H. provided the *Il6^{fl/fl}* mice and edited the manuscript. P.G.F. provided
388 the *Pdl1^{fl/fl}* mice and edited the manuscript. N.C. had full access to all of the data in the study and
389 take responsibility for the integrity of the data and the accuracy of the data analysis. All authors
390 approved the final version of the article.

391 **Declaration of interests:**

392 N.C. holds a patent related to compositions and methods for treating or preventing lupus
393 (W020120710042). C.P. and N.C. are coinventors of the patent WO2016128565A1 related to the use
394 of PTGDR-1 and PTGDR-2 antagonists for the prevention or treatment of systemic lupus
395 erythematosus. No other disclosures relevant to this article are reported.

396 **FIGURE TITLES AND LEGENDS**

397 **Figure 1: Human blood basophils from SLE patients overexpress PD-L1**

398 (a) Flow cytometry gating strategy used to identify human circulating T follicular helper T cells (TFH)
399 defined as CD3⁺ CD8 α ⁻ CD4⁺ CXCR5⁺ ICOS⁺ PD-1⁺. Among TFH cells, TFH1 cells were defined as
400 CXCR3⁺CCR6⁻, TFH2 as CXCR3⁻ CCR6⁻, and TFH17 as CXCR3⁻ CCR6⁺. (b) Proportions (%) among CD4⁺ T
401 cells of TFH as defined in (a) in blood from healthy controls (CT) and inactive (inact.), mild, or active
402 SLE patients (n = 16/11/12/21, respectively) as determined by flow cytometry. (c) Proportions (%)
403 among CD4⁺ T cells of TFH2 as defined in (a) in blood from healthy controls and inactive, mild, or
404 active SLE patients (n = 16/10/12/20, respectively) as determined by flow cytometry. (d) **Left**,
405 Histogram plot representing the CD203c expression levels on blood basophils from a healthy control
406 (CT, black line), a patient with active SLE (red line), and isotype control staining (grey filled
407 histogram). **Right**, CD203c expression levels on blood basophils from CT and inact., mild or active SLE
408 patients (n = 43/61/46/98, respectively) as determined by flow cytometry. (e) **Left**, Representative
409 histogram plot of PD-L1 expression levels on blood basophils as in (d). **Right**, PD-L1 expression levels
410 on blood basophils from CT and inact., mild or active SLE patients (n = 39/60/45/96, respectively) as
411 determined by flow cytometry. (b-e) Data are presented as violin plots with median (plain line) and
412 quartiles (dotted lines). Statistical analyses were Kruskal-Wallis tests followed by Dunn's multiple
413 comparisons tests. NS: not significant, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. A.U.:
414 arbitrary units.

415

416 **Figure 2: Basophil-TFH functional relationship during lupus-like disease**

417 (a) PD-L1 expression levels on basophils from PBS-injected (blue bars) or pristane-injected *Mcpt8^{DTR}*
418 mice (red bars) in the indicated compartments as determined by flow cytometry using the gating
419 strategy described in **Fig. S2a,b**. A representative FACS histogram of PD-L1 expression on spleen
420 basophils from a PBS-injected mouse (blue line), a pristane-injected mouse (red line), and the signal

421 from the isotype control (grey filled) is shown. **(b)**, PD-L1 expression levels on basophils from an aged
422 *Mcpt8^{DTR}* (blue bars) or aged *Lyn^{-/-} Mcpt8^{DTR}* mice (red bars) in the indicated compartments as in **(a)**.
423 A representative FACS histogram of PD-L1 expression on spleen basophils from an aged *Mcpt8^{DTR}*
424 (blue line), an aged *Lyn^{-/-} Mcpt8^{DTR}* mouse (red line), and the signal from the isotype control (grey
425 filled) is shown. **(c)** Proportions (%) of TFH among CD4⁺ T cells in the indicated compartments from
426 PBS-injected (blue bars) and basophil sufficient (DT-) or basophil-depleted (DT+) mice and from
427 pristane-injected *Mcpt8^{DTR}* mice (red bars) DT treated or not. Data were determined by flow
428 cytometry using the gating strategy described in **Fig. S2c,d**. **(d)** Proportions (%) of TFH among CD4⁺ T
429 cells in the indicated compartments from aged *Mcpt8^{DTR}* (blue bars) and basophil sufficient (DT-) or
430 basophil-depleted (DT+) mice and from aged *Lyn^{-/-} Mcpt8^{DTR}* mice (red bars) DT-treated or not. Data
431 were determined by flow cytometry as in **(c)**. **(e)** Proportions (%) of basophils in the indicated
432 compartments in the same mice as described in **(c)** were determined by flow cytometry as in **(a)**. **(f)**
433 Proportions (%) of basophils in the indicated compartments in the same mice as described in **(d)**
434 were determined by flow cytometry as in **(a)**. **(g)** Anti-RNP IgG autoantibody plasma titers from the
435 same mice as in **(c)** were quantified by ELISA, as described in the methods section. O.D. values at 450
436 nm were determined and data were normalized to the mean of PBS-injected DT – *Mcpt8^{DTR}* values.
437 **(h)** Anti-dsDNA IgG autoantibody plasma titers from the same mice as in **(d)** were quantified by ELISA,
438 as described in the methods section. O.D. values at 450 nm were determined and data were
439 normalized to the mean of DT – *Mcpt8^{DTR}* values. A.U.: arbitrary units. **(i)** Proportions (%) of TFH
440 among CD4⁺ T cells in the indicated compartments from basophil-sufficient (*Mcpt8^{CT/CT} R26^{+/+}*) (blue
441 bars) or basophil-deficient (*Mcpt8^{CT/+} R26^{DTA/+}*) (red bars) mice treated with PBS or pristane (pristane
442 – or +, respectively). Data were determined by flow cytometry as in **(c)**. **(a-i)** Results are from at least
443 three independent experiments and presented as individual values in bars representing the mean
444 values. Statistical analyses were done by one-way ANOVA followed by Holm-Šidák's multiple
445 comparisons test between the indicated groups. NS: not significant, p>0.05; *: p<0.05; **: p<0.01;
446 ***: p<0.001; ****: p<0.0001.

447

448 **Figure 3: Basophils control TFH abilities to produce IL-21 and IL-4 in the lupus-like context**

449 Splenocytes from the indicated mice were stimulated with PMA and Ionomycin (P/I +) or not (P/I-) as
450 described in the methods section. Intracellular flow cytometry was realized to visualize the indicated
451 cytokine productions on the indicated cellular compartments. **(a,d)** Representative contour plots
452 showing PMA-Ionomycin-induced IFN γ , IL-21, and IL-4 productions by TFH cells (as defined in **Fig. 2c**)
453 in splenocytes from aged *Mcpt8^{DTR}* or *Lyn^{-/-} Mcpt8^{DTR}* mice depleted in basophils (DT+) or not (DT-)
454 (see **methods**). **(b,e,g)** Proportions (%) of IL-21 **(b)**, IL-4 **(e)**, and IFN γ **(g)** producing cells among TFH
455 cells in splenocytes stimulated with PMA and Ionomycin (P/I +) or not (P/I-) from aged *Mcpt8^{DTR}*
456 (blue bars) or *Lyn^{-/-} Mcpt8^{DTR}* (red bars) mice depleted in basophils (DT+, lighter color) or not (DT-,
457 darker color). **(c,f,h)** Proportions (%) of IL-21 **(c)**, IL-4 **(f)**, and IFN γ **(h)** producing cells among TFH cells
458 in splenocytes stimulated with PMA and Ionomycin (P/I +) or not (P/I-) from PBS-injected mice (blue
459 bars) and pristane-injected *Mcpt8^{DTR}* mice (red bars), basophil sufficient (DT-, darker color) or
460 basophil-depleted (DT+, lighter color). **(i)** Representative contour plots showing non-stimulated (NS)
461 and PMA-Ionomycin-induced (P/I) IL-6 and IL-4 productions by spleen basophils from aged *Mcpt8^{DTR}*
462 or *Lyn^{-/-} Mcpt8^{DTR}* mice. **(j,k)** Proportions (%) of IL-6 **(j)** and IL-4 **(k)** producing cells among basophils in
463 splenocytes stimulated with PMA and Ionomycin (P/I +) or not (P/I-) from aged *Mcpt8^{DTR}* (blue bars)
464 or *Lyn^{-/-} Mcpt8^{DTR}* (red bars) mice. **(l,m)** Proportions (%) of IL-6 **(l)** and IL-4 **(m)** producing cells among
465 basophils in splenocytes stimulated with PMA and Ionomycin (P/I +) or not (P/I-) from PBS-injected
466 *Mcpt8^{DTR}* (blue bars) or pristane-injected *Mcpt8^{DTR}* (red bars) mice. **(b,c, e-h and j-m)** Results are from
467 at least three independent experiments and presented as individual values in bars representing the
468 mean values. **(b,c, e-h)** Statistical analyses were done by one-way ANOVA followed by Holm-Šidák's
469 multiple comparisons test between the indicated groups. **(j-m)** Statistical analyses were done by
470 Mann-Whitney U test between the indicated groups. NS: not significant, $p > 0.05$; *: $p < 0.05$; **:
471 $p < 0.01$; ***: $p < 0.001$; ****: $p < 0.0001$.

472

473 **Figure 4: A bidirectional crosstalk between basophils and CD4⁺ T cells promotes *ex vivo* TFH**

474 **differentiation**

475 (a-k) Purified wild-type naïve CD4⁺ T cells were cultured in plates coated with anti-CD3 and anti-CD28
476 antibodies for three days without (–, grey filled bars) or with purified basophils from the following
477 mice: *Mcpt8*^{CT/+} (WT) (blue filled bars), *Mcpt8*^{CT/+} *Il4*^{fl/fl} (*Il4*^{fl/fl}, IL-4-deficient basophils) (red filled bars),
478 *Mcpt8*^{CT/+} *Il6*^{fl/fl} (*Il6*^{fl/fl}, IL-6-deficient basophils) (orange filled bars), or *Mcpt8*^{CT/+} *Pdl1*^{fl/fl} (*Pdl1*^{fl/fl}, PD-L1-
479 deficient basophils) (green filled bars). (a) Proportions (%) of TFH among CD4⁺ T cells after three days
480 of culture as described in **methods**. (b-e) Proportions (%) of IL-21- (b), IL-6- (c), IL-4- (d), and IL-13- (e)
481 producing cells among TFH cells non-restimulated and incubated with brefeldin A for the last 4 hours
482 of the culture. (f) Representative histograms of PD-L1 expression on purified spleen basophils, from
483 mice with the indicated genotype, co-cultured for three days without (dotted lines) or with activated
484 naïve CD4 T cells (solid lines) (as described above). (g) PD-L1 expression levels on basophils, from
485 mice as described above, cultured without (–, light colors) or with (+, dark colors) purified wild-type
486 CD3/CD23-activated naïve CD4⁺ T cells for three days. (h) Representative contour plots showing IL-6
487 and IL-4 spontaneous production of basophils of the indicated genotype after three days of culture
488 without (–) or with activated CD4+ T cells and in the presence of brefeldin A for the last 4 hours of
489 culture. (i,j,k) Proportions (%) of spontaneous IL-4- (i), IL-6- (j), and IL-13- (k) producing cells among
490 basophils of the indicated genotypes cultured as described above. (a-k) Results for the same cells but
491 re-stimulated with PMA and ionomycin are shown in **Fig. S4d-j**. (a-e, g, i-k) Results are from at least
492 three independent experiments and presented as individual values in bars representing the mean ±
493 s.e.m.. (a) Statistical analyses were done by a Kruskal-Wallis test followed by Dunn's multiple
494 comparisons tests. (b-e, g, i-k) Statistical analyses were done by Mann-Whitney U test between the
495 indicated groups. NS: not significant, p>0.05; *: p<0.05; **: p<0.01; ***: p<0.001; ****: p<0.0001.

496

497 **Figure 5: PD-L1 controls the basophil-TFH functional relationship during lupus-like disease**

498 (a) Proportions (%) of TFH among CD4⁺ T cells in spleen (left) and lymph nodes (right) from *Mcpt8*^{CT/+}
499 (WT) (blue filled bars) or *Mcpt8*^{CT/+} *Pd11*^{fl/fl} (*Pd11*^{fl/fl}) (red filled bars) mice injected with PBS (–) or with
500 pristane (+). (b) Proportions (%) of basophils among CD45⁺ cells in the spleen (left) and lymph nodes
501 (right) from the mice described in (a). (c,d) Proportions (%) of spontaneous IL-4⁺ (c) or IL-6⁺ cells (d)
502 among basophils in the spleen from the mice described in (a) incubated 4 hours in the presence of
503 brefeldin A. (e) Proportions (%) of CD19⁺CD138⁺ cells among CD45⁺ cells in spleen from the mice
504 described in (a). (f) Anti-RNP IgG autoantibody plasma titers from the same mice as in (a) were
505 quantified by ELISA, as described in the methods section. O.D. values at 450 nm were determined
506 and data were normalized to the mean of PBS-injected *Mcpt8*^{CT/+} values. (g,h) Left, Representative
507 pictures of one glomerulus from mice with the indicated genotypes treated without (PBS, –) or with
508 pristane (+) showing the intensity of anti-IgG (g) or anti-C3 (h) staining by immunofluorescence. Scale
509 bar = 50 μm. Uncropped images are shown in Fig. S6a (IgG) and S6b (C3). Right, quantification of IgG
510 (g) and C3 (h) glomerular deposits in kidneys from the mice described in (a). (a-h) Results are from at
511 least three independent experiments and presented as individual values in bars representing the
512 mean values. Statistical analyses were done by unpaired Student t-tests between the indicated
513 groups. NS: not significant, p>0.05; *: p<0.05; **: p<0.01; ***: p<0.001; ****: p<0.0001.

514

515 **Figure 6: Basophil-derived IL-4 controls T-dependent autoreactive antibody isotype switch in lupus-**
516 **like disease**

517 (a) Proportions (%) of TFH among CD4⁺ T cells in spleen (left) and lymph nodes (right) from *Mcpt8*^{CT/+}
518 (WT) (blue filled bars) or *Mcpt8*^{CT/+} *Il4*^{fl/fl} (*Il4*^{fl/fl}) (red filled bars) mice injected with PBS (–) or with
519 pristane (+). (b) Proportions (%) of basophils among CD45⁺ cells in the spleen (left) and lymph nodes
520 (right) from the mice described in (a). (c) Proportions (%) of CD19⁺CD138⁺ cells among CD45⁺ cells the
521 in the spleen (left) and lymph nodes (right) from the mice described in (a). (d) Proportions (%) of

522 spontaneous IL-6⁺ cells among basophils in the spleen from the mice described in (a) incubated 4
523 hours in the presence of brefeldin A. (e) Anti-RNP IgG autoantibody plasma levels from the same
524 mice as in (a) were quantified by ELISA, as described in the methods section. O.D. values at 450 nm
525 were determined and data were normalized to the mean of PBS-injected *Mcpt8*^{CT/+} values. (f)
526 Quantification of C3 (left) and IgG (right) glomerular deposits in kidneys from the mice described in
527 (a). A representative picture for each genotype in each condition is shown in Fig. S6a,b. (a-f) The data
528 shown that concerns *Mcpt8*^{CT/+} (WT) mice are the same as the data shown in Fig. 5. (g) Anti-RNP IgM
529 autoantibody plasma levels were determined by ELISA, as described in the methods section. O.D.
530 values at 450 nm were determined and data were normalized to the mean of the values of PBS-
531 injected control mice for each genotype. The mice analyzed were *Mcpt8*^{CT/+} (WT), *Mcpt8*^{CT/+} *Il4*^{fl/fl}
532 (*Il4*^{fl/fl}), *Mcpt8*^{CT/+} *Pdl1*^{fl/fl} (*Pdl1*^{fl/fl}) (green filled bars) and basophil-deficient (*Mcpt8*^{CT/+} *R26*^{DTA/+})
533 (*R26*^{DTA/+}, grey filled bars) mice treated with PBS or pristane (pristane – or +, respectively). (h)
534 Representative pictures of kidneys from mice with the indicated genotypes injected with PBS or
535 pristane showing the intensity of anti-IgM staining by immunofluorescence. Scale bar = 200 μm. (i)
536 Quantification of IgM glomerular deposits in kidneys from the mice described in (g). (a-i) Results are
537 from at least three independent experiments and presented as individual values in bars representing
538 the mean values. (a-g,i) Statistical analyses were done by unpaired Student t-tests between the
539 indicated groups. NS: not significant, p>0.05; *: p<0.05; **: p<0.01; ***: p<0.001; ****: p<0.0001.

540

541 **Figure 7: Human basophils drive TFH differentiation through IL-4, IL-6, and PD-L1 dependent**
542 **mechanisms *ex vivo***

543 (a,b) Representative contour plots showing CD3/CD28-activated human CD4⁺ T cells cultured for
544 three days without (a) or with (b) purified human basophils at a 5:1 ratio (left panels) and the
545 condition-induced TFH differentiation of the CD4⁺ T cells (right panels). Basophils were defined as
546 FcεRIα⁺ CRTH2⁺ CCR3⁺ cells and TFH cells were defined as CD4⁺ PD1⁺ CXCR5⁺ ICOS⁺ cells. (c)

547 Proportions (%) of TFH among CD3/CD28-activated CD4⁺ T cells after three days of culture without
548 (0:1) or with the indicated ratio of purified human basophils. **(d)** Proportions (%) of TFH cells among
549 CD3/CD28-activated CD4⁺ T cells after three days of culture without (CD4⁺ T cells alone) or with
550 purified human basophils at a ratio of 1:5 in the absence (–) (blue filled bars) or presence of
551 antibodies blocking IL-4 (αIL-4) (red filled bars), IL-6 (αIL-6) (orange filled bars) or PD-1 (αPD-1) (green
552 filled bars) or the corresponding isotype controls (Iso) (blue filled bars). **(e)** Representative contour
553 plots showing subsets of TFH cells as defined in the upper left panel based on CCR6 and CXCR3
554 expressions on cells as in **(a)**. **(f)** Proportions (%) of TFH2 cells among TFH cells after culture as
555 described in **(d)**. TFH2 cells were defined as CD4⁺ PD1⁺ CXCR5⁺ ICOS⁺ CCR6[–] CXCR3[–] cells. **(c,d)** Data
556 are presented as individual values in bars representing the mean values ± s.e.m. **(c)** One
557 representative experiment with cells from 4 different donors is shown. **(d,f)** Results are from three
558 independent experiments. **(c,d,f)** Statistical analyses were done by one-way ANOVA test followed by
559 Tukey's multiple comparisons tests between the indicated groups. NS: not significant, p>0.05; **:
560 p<0.01; ***: p<0.001; ****: p<0.0001.

561

562

563 MATERIAL AND METHODS

564 Patients

565 Blood samples were collected from adult patients enrolled in a prospective long-term study of
566 systemic lupus erythematosus (SLE) and chronic renal diseases. All SLE patients fulfilled the American
567 College of Rheumatology (ACR) classification criteria for SLE. SLE and healthy control (CT) donor
568 characteristics are shown in **Table S1**. SELENA-SLEDAI (Safety of Estrogens in Lupus Erythematosus
569 National Assessment - SLE Disease Activity Index) scores were assessed to evaluate patients' lupus
570 activity who were classified as inactive (0-1), mild (2-4), and active (> 4). The study was approved by
571 the Comité Régional de Protection des Personnes (CRPP, Paris, France) under the reference ID-RCB
572 2014-A00809-38. SLE samples were obtained from in- and outpatients and clinical data were
573 harvested after approval by the Commission Nationale de l'Informatique et des Libertés (CNIL). All
574 samples were collected in heparinized tubes (BD vacutainer) and processed within 4 hours. Written
575 informed consent was obtained from all individuals.

576 Mice

577 *Mcpt8^{DTR}*⁴³, *Lyn^{-/-} Mcpt8^{DTR}*^{11,44}, *Il4^{fl/fl}*²², *Il6^{fl/fl}*²³, and *Pdl1^{fl/fl}*²⁴ mice were on a pure C57BL/6J
578 background and bred in our animal facilities. Rosa26-loxP-Stop-loxP-DTA C57BL/6J (*R26^{DTA/DTA}* or *R26^{DTA/+}*)
579 mice⁴⁵ were purchased from The Jackson Laboratory through Charles River Laboratories. CT-M8
580 (*Mcpt8^{tm1.1(cre)lcs}* or *Mcpt8^{CT/CT}* or *Mcpt8^{CT/+}*) mice were recently described¹². The mice crossed in our
581 animal facilities (*Mcpt8^{CT/+}*, *Mcpt8^{CT/+} Il4^{fl/fl}*, *Mcpt8^{CT/+} Il6^{fl/fl}*, *Mcpt8^{CT/+} Pdl1^{fl/fl}* and *Mcpt8^{CT/+} R26^{DTA/+}*)
582 were on a C57BL6J/N mixed genetic background at the F2 generation. For lupus-like disease analysis
583 of the *Lyn^{-/-}* model, "aged" *Mcpt8^{DTR}* and *Lyn^{-/-} Mcpt8^{DTR}* age-matched and sex-matched mice
584 were analyzed between 30 and 45 weeks of age (50% males and 50 % females). Mice were
585 maintained under specific pathogen-free conditions in our animal facilities. The study was conducted
586 in accordance with the French and European guidelines and approved by the local ethics committee

587 comité d'éthique Paris Nord N°121 and the Ministère de l'enseignement supérieur, de la recherche
588 et de l'innovation under the authorization number APAFIS#14115.

589 **Human samples handling**

590 Heparinized human blood samples were centrifuged at 600 g for 5 minutes and 2 mL of plasma were
591 collected and stored at -80°C for later analysis. Red blood cells (RBC) were lysed in RBC lysing buffer
592 (150 mM NH₄Cl, 12 mM NaHCO₃, 1 mM EDTA, pH 7.4) in a ratio of 5mL of blood for 20mL of ACK
593 lysing buffer. After 5 min of incubation at room temperature (rt), 25mL of PBS were added and cells
594 were centrifuged at 600 g for 5 min, and the supernatant was discarded. This procedure was
595 repeated 3 times. Leukocytes were then resuspended in fluorescence-activated cell sorting (FACS)
596 buffer (PBS 1% BSA, 0.01% NaN₃, 1mM EDTA) and prepared for flow cytometry (see below).
597 Leukocyte count and viability (>95%) were assessed by trypan-blue staining on a Malassez
598 hemacytometer.

599 **Pristane-induced lupus-like mouse model**

600 Pristane-induced lupus-like disease was initiated by injecting 500 µL of 2,6,10,14-
601 tetramethylpentadecane or Pristane (Sigma) into the peritoneal cavity of 7-10 weeks-old female
602 mice. For control individuals, genotype- and age-matched female mice were injected with 500 µL of
603 phosphate buffer saline pH 7.4 (PBS) (Gibco). Mice were attributed to PBS- or pristane-injected
604 groups randomly and maintained in the same cage for the whole procedure. Pristane- and PBS-
605 injected mice were analyzed 8 weeks after injection.

606 **DT-mediated basophil depletion in lupus-like context**

607 For diphtheria toxin (DT)-mediated basophil depletion, *Mcpt8^{DTR}*, and *Lyn^{-/-} Mcpt8^{DTR}* mice were
608 injected intraperitoneally with 100 µL of PBS containing (or not) 1 µg of DT (Sigma) 10, 9, 6, 2 and 1
609 day before the sacrifice.

610 **Mouse OVA immunization experiments**

611 10 to 15 weeks old C57/BL6J *Mcpt8^{DTR}* sex-matched mice were immunized by intraperitoneal
612 injection of 200 μ L of a 50/50 emulsion of Alum (ThermoFisher Scientific) with 100 μ g of ovalbumin
613 (OVA, Sigma-Aldrich) diluted in PBS or with PBS alone for control mice. A similar injection was
614 performed on day 7 and the mice were sacrificed on day 14. For DT-mediated basophil depletion, 1
615 μ g of DT (or PBS as a control) was injected intraperitoneally on day 12 and day 13.

616 **Mouse samples processing**

617 Mice were euthanized in a controlled CO₂ chamber (TEM Segal) and blood sampling was performed
618 through cardiac puncture with a heparin-coated syringe with a 25G needle. Blood was centrifuged at
619 300 g for 15 min and plasma was harvested and kept at -80°C for later analysis. RBC were lysed in
620 5mL of RBC lysing buffer for 5 min at rt and washed with 10mL of PBS. This procedure was repeated 3
621 times and cells were resuspended in PBS. The left kidney was harvested and embedded in OCT
622 embedding matrix (Cellpath) and snap-frozen in liquid nitrogen and kept at -80°C for later analysis.
623 Spleen and lymph nodes (cervical, brachial and inguinal) were harvested in PBS and dissociated by
624 mechanical disruption on a 40 μ m cell strainer (Falcon, Corning). For splenocytes, RBC were lysed
625 once in 5mL RBC lysing buffer 5 min at rt and washed with 10mL of PBS. Cell counts were assessed by
626 trypan-blue staining on a Malassez hemacytometer and 1 to 5 million cells were used per FACS
627 staining condition.

628 ***Ex vivo* stimulation of splenocytes.**

629 Mouse splenocytes were harvested as described above and resuspended at 5 million cells/mL in
630 culture medium (RPMI 1640 with Glutamax and 20mM HEPES, 1mM Na-pyruvate, non-essential
631 amino acids 1X (all from Life Technologies), 100 μ g/mL streptomycin and 100 U/mL penicillin (GE
632 Healthcare) and 37.5 μ M β -mercaptoethanol (Sigma-Aldrich) supplemented with 20% heat-
633 inactivated fetal calf serum (FCS) (Life Technologies)). For phorbol-myristate-acetate (PMA) and
634 ionomycin stimulation experiments, whole splenocytes were stimulated or not with 40 nM of PMA
635 and 800 nM ionomycin for 4 hours in the presence of 2 μ g/mL of brefeldin A (all from Sigma Aldrich,

636 Merck) and cultured at 37°C and 5% CO₂. Then, cells were harvested by repeated flushing, and wells
637 were washed with 1mL of PBS. Samples were then prepared for flow cytometry analysis.

638 **Flow cytometry staining**

639 For human leukocytes, non-specific antibody binding sites were saturated with 20 µL of a solution
640 containing 100 µg/mL of human, mouse, rat, and goat IgG (Jackson ImmunoResearch Europe and
641 Innovative Research Inc.) in FACS buffer. 200 µL of staining solution containing the panel of
642 fluorophore-conjugated specific antibodies or their fluorophore-conjugated isotypes (described in
643 the **antibodies and reagents table**) were added to the cells for 30 min at 4°C protected from light.
644 After a wash in PBS, cells were fixed in fixation buffer (Biolegend) for 20 minutes at 4°C and then
645 washed in FACS buffer before data acquisition. For mouse samples, cells washed in PBS were stained
646 with GHOST 510 viability dye (TONBO) following the manufacturer's instructions. Non-specific
647 antibody binding sites were saturated with 10 µg/mL of anti-CD16/CD32 antibody clone 2.4G2
648 (BioXCell), and 100 µg/mL of polyclonal rat, mouse, and Armenian Hamster IgG (Innovative Research
649 Inc.) in FACS buffer and stained with the antibodies described in the **antibodies and reagents table**
650 for 30 min in the dark at 4°C. Cells were then washed in FACS Buffer before data acquisition. For
651 intracellular staining, cells were first stained extracellularly as described above. Cells were washed in
652 PBS and fixed with fixation buffer for 20 min at 4°C. Cell permeabilization and intracellular staining
653 were realized with permeabilization/wash buffer (Biolegend) following the manufacturer's
654 instructions. Cells were then resuspended in FACS buffer before acquisition All flow cytometry
655 acquisitions were realized using a Becton Dickinson 5 lasers LSR Fortessa X-20 and data analysis using
656 Flowjo vX (Treestar, BD Biosciences). For assessment of surface marker expression levels, ratios of
657 the geometric mean fluorescence intensity (gMFI) of the markers to the gMFI of the corresponding
658 isotype control were calculated and expressed in arbitrary units (A.U.).

659 **Kidney Immunofluorescence assays**

660 4 μm thick cryosections of OCT-embedded kidneys were fixed 20 min in ice-cold acetone and kept a -
661 80°C until immunofluorescence staining. Slides were thawed and fixed in 10% formalin (Sigma) for 20
662 min at room temperature and blocked with PBS containing 1% BSA (Euromedex) and 5% goat serum
663 (Sigma-Aldrich). Slices were stained for 2 hours at room temperature in the dark in a humid chamber
664 with FITC-conjugated anti-mouse C3 (Cedarlane), Alexa Fluor® 488-conjugated anti-mouse C3 (Santa
665 Cruz Biotech), Alexa Fluor® 488-conjugated goat anti-mouse IgG Fc γ -specific (Jackson
666 Immunoresearch), FITC-conjugated goat anti-mouse IgM (BioRad (AbD Serotec)) or corresponding
667 isotype controls. Slides were mounted in Immunomount (ThermoFischer Scientifics) and analyzed by
668 fluorescent microscopy (Leica DMR, Leica microsystems). The ratio of specific glomerular
669 fluorescence over tubulointerstitial background was then measured using ImageJ software v. 1.43u
670 (NIH), averaging at least 30 glomeruli per mouse for each sample.

671 **Anti-RNP IgG and IgM autoantibody detection**

672 Maxisorp 96 well plates (Thermo Scientific) were coated overnight at 4°C with 10 $\mu\text{g}/\text{mL}$ of purified
673 RNP complexes (Immunovision) diluted in carbonate buffer (100 mM NaHCO_3 and 30 mM Na_2CO_3 pH
674 9.6). Plates were washed 3 times in PBS containing 0.1% of Tween-20 (Bio-Rad laboratories) (PBS-T)
675 and saturated for 1 hour with PBS containing 5% of FCS. For anti-RNP IgG quantification, plasma
676 samples were diluted 1:25 in PBS-T containing 5% of goat serum and 100 μL added to the wells.
677 Samples, positive and negative controls were incubated for 2 hours at rt. Plates were washed 5 times
678 with PBS-T. 100 μL of either 500 ng/mL goat anti-mouse IgG (Invitrogen) or 10 ng/mL goat anti-
679 mouse IgM (Bethyl laboratories) conjugated to horseradish peroxidase (HRP) diluted in PBS-T
680 containing 5% goat serum were added and incubated 1h at room temperature. After 5 washes in
681 PBS-T, 100 μL of tetramethylbenzidine (TMB) substrate (ThermoFisher) were added to the wells and
682 incubated at least 20 min at rt and the reaction was stopped with 0.2N sulfuric acid solution. Optical
683 density at 450 nm was measured by spectrophotometry (Infinite 200 Pro plate reader, TECAN). On
684 each plate, similar negative and positive controls were run. Optical density (OD) values were first

685 normalized to the negative controls and then, the presented results were normalized to the mean of
686 the control mice values and expressed in arbitrary units (A.U.).

687 **Anti-dsDNA IgG detection**

688 Maxisorp 96 well plates (Thermo Scientific) were coated overnight at 4°C with calf thymus dsDNA
689 (Sigma-Aldrich) diluted in TE buffer (Tris-HCl 10 mM, EDTA 1 mM pH 9) at a concentration of 2 µg/mL
690 and diluted in the same volume of Pierce DNA coating solution (Thermo Scientific) to obtain a final
691 concentration of 1µg/mL of dsDNA. The same protocol as for anti-RNP IgG was then followed but the
692 PBS-T contained 0.05% of Tween-20.

693 **Cell sorting and co-culture**

694 For mouse co-culture experiments, F(ab')₂ anti-CD3 (clone145-2C11 at 0,5 µg/mL) and anti-CD28
695 (clone PV-1 at 0,5 µg/mL) antibodies (BioXcell) were coated overnight at 4°C in culture 96 well plates
696 (Costar) in sterile-filtered coating buffer (20 mM carbonate buffer (pH 9.6) containing 2 mM MgCl₂
697 and 0.01% NaN₃). Wells were washed in PBS before plating the cells. Spleens were harvested and
698 handled as described above and resuspended at 10⁸ cells/mL in PBS containing 2% FCS and 2mM
699 EDTA. Naïve CD4⁺ T cells were sorted by magnetic negative selection following manufacturer
700 protocol (Stemcell Technologies) and resuspended in culture medium at 0.5 million cells/mL. 100 µL
701 of naïve CD4⁺ T cell suspension were then added to wells of interest. Basophils from CTM8 mice were
702 purified over 98% by electronic sorting using the BD FACSMelody Cell Sorter (BD Biosciences) using
703 the tandem tomato fluorescent protein as a specific marker¹². Basophils were re-suspended in
704 culture medium at 0.1 million cells/mL and 100µL were added to wells of interest. All wells were
705 supplemented with 10 pg/mL of recombinant mouse IL-3 (Peprotech). After 3 days of culture at 37°C
706 5% CO₂, cells were harvested and prepared for flow cytometry as described above. For cytokine
707 production detection, cells were stimulated or not for the last 4 hours with 40 nM PMA and 800 nM
708 ionomycin in the presence of 2 µg/mL brefeldin A (Sigma-Aldrich, Merck) and prepared for flow
709 cytometry as described above.

710 For human co-culture experiments, 96 well plates (Costar) were coated overnight at 4°C in coating
711 buffer containing 5 µg/mL of mouse anti-human CD3 (clone OKT3) (Thermo Fischer Scientific). Blood
712 from healthy volunteers was handled and lysed as described above in sterile conditions and re-
713 suspended at 5×10^7 cells/mL in PBS 2% FCS (Gibco) 2mM EDTA. Naïve CD4⁺ T cells and basophils
714 were sorted by magnetic negative selection following manufacturer instructions (Stemcell
715 Technologies). Naïve CD4⁺ T cells were re-suspended in culture medium at 0.5 million cells/mL. and
716 100 µL of cell suspension were then added to each well. Basophils were resuspended in culture
717 medium at 0.1 million cells/mL and 100µL were added to each well unless otherwise specified. All
718 wells were supplemented with 10 pg/ml of recombinant human IL-3 (Biolegend) and 2 µg/mL of
719 mouse anti-human CD28 antibody (Clone CD28.2 at (BioXcell)). When indicated, some wells were
720 supplemented with mouse anti-human blocking antibodies targeting IL4 (Clone MP4-25D2), IL-6
721 (Clone MQ2-13A5), both at 5 µg/mL or PD-1 (Clone EH12.2H7 at 10µg/mL) or with the corresponding
722 isotypes at the same concentrations. Cells were harvested after 3 days of culture at 37°C 5% CO₂ and
723 prepared for flow cytometry as described above.

724 **Statistical analysis**

725 Two-tailed Student's unpaired t-tests were used to compare the differences of one variable between
726 two groups when distributions were Gaussian and Mann-Whitney U tests for non-parametric
727 distributions. When more than two groups were compared, one-way ANOVA coupled with *ad hoc*
728 multiple comparisons post-tests, as indicated in the figure legends depending on the distribution of
729 the values in each group, were used. Statistical analyses were realized using Prism v9.4 software
730 (Graphpad).

731 **Antibodies, reagents, software and equipments**

732 See Supplementary Table S3.

733

734 REFERENCES

- 735 1. Anders, H.J., *et al.* Lupus nephritis. *Nat Rev Dis Primers* **6**, 7 (2020).
736 2. Tsokos, G.C. Autoimmunity and organ damage in systemic lupus erythematosus. *Nat*
737 *Immunol* **21**, 605-614 (2020).
738 3. Murphy, G. & Isenberg, D.A. Biologic therapies for systemic lupus erythematosus: where are
739 we now? *Curr Opin Rheumatol* **32**, 597-608 (2020).
740 4. Gensous, N., Schmitt, N., Richez, C., Ueno, H. & Blanco, P. T follicular helper cells, interleukin-
741 21 and systemic lupus erythematosus. *Rheumatology (Oxford)* **56**, 516-523 (2017).
742 5. Kim, S.J., Lee, K. & Diamond, B. Follicular Helper T Cells in Systemic Lupus Erythematosus.
743 *Front Immunol* **9**, 1793 (2018).
744 6. Kurata, I., Matsumoto, I. & Sumida, T. T follicular helper cell subsets: a potential key player in
745 autoimmunity. *Immunol Med* **44**, 1-9 (2021).
746 7. Mountz, J.D., Hsu, H.C. & Ballesteros-Tato, A. Dysregulation of T Follicular Helper Cells in
747 Lupus. *J Immunol* **202**, 1649-1658 (2019).
748 8. Jacquemin, C., *et al.* OX40L/OX40 axis impairs follicular and natural Treg function in human
749 SLE. *JCI Insight* **3**(2018).
750 9. Shi, J., *et al.* PD-1 Controls Follicular T Helper Cell Positioning and Function. *Immunity* **49**,
751 264-274 e264 (2018).
752 10. Charles, N., Hardwick, D., Daugas, E., Illei, G.G. & Rivera, J. Basophils and the T helper 2
753 environment can promote the development of lupus nephritis. *Nat Med* **16**, 701-707 (2010).
754 11. Pellefigues, C., *et al.* Prostaglandin D2 amplifies lupus disease through basophil accumulation
755 in lymphoid organs. *Nat Commun* **9**, 725 (2018).
756 12. Tchen, J., *et al.* CT-M8 Mice: A New Mouse Model Demonstrates That Basophils Have a
757 Nonredundant Role in Lupus-Like Disease Development. *Front Immunol* **13**, 900532 (2022).
758 13. Pellefigues, C., Tchen, J., Saji, C., Lamri, Y. & Charles, N. AMG853, A Bispecific Prostaglandin
759 D2 Receptor 1 and 2 Antagonist, Dampens Basophil Activation and Related Lupus-Like
760 Nephritis Activity in Lyn-Deficient Mice. *Front Immunol* **13**, 824686 (2022).
761 14. Le Coz, C., *et al.* Circulating TFH subset distribution is strongly affected in lupus patients with
762 an active disease. *PLoS One* **8**, e75319 (2013).
763 15. Kim, C.J., *et al.* The Transcription Factor Ets1 Suppresses T Follicular Helper Type 2 Cell
764 Differentiation to Halt the Onset of Systemic Lupus Erythematosus. *Immunity* **49**, 1034-1048
765 e1038 (2018).
766 16. Pan, Q., *et al.* Basophil Activation-Dependent Autoantibody and Interleukin-17 Production
767 Exacerbate Systemic Lupus Erythematosus. *Front Immunol* **8**, 348 (2017).
768 17. Cannons, J.L., Tangye, S.G. & Schwartzberg, P.L. SLAM family receptors and SAP adaptors in
769 immunity. *Annu Rev Immunol* **29**, 665-705 (2011).
770 18. Dema, B., *et al.* Basophils contribute to pristane-induced Lupus-like nephritis model. *Sci Rep*
771 **7**, 7969 (2017).
772 19. Otsuka, A., *et al.* Basophils are required for the induction of Th2 immunity to haptens and
773 peptide antigens. *Nat Commun* **4**, 1739 (2013).
774 20. Denzel, A., *et al.* Basophils enhance immunological memory responses. *Nat Immunol* **9**, 733-
775 742 (2008).
776 21. Miyake, K., Shibata, S., Yoshikawa, S. & Karasuyama, H. Basophils and their effector
777 molecules in allergic disorders. *Allergy* (2020).
778 22. Shibata, S., *et al.* Basophils trigger emphysema development in a murine model of COPD
779 through IL-4-mediated generation of MMP-12-producing macrophages. *Proc Natl Acad Sci U*
780 *S A* **115**, 13057-13062 (2018).
781 23. Quintana, A., *et al.* Astrocyte-specific deficiency of interleukin-6 and its receptor reveal
782 specific roles in survival, body weight and behavior. *Brain Behav Immun* **27**, 162-173 (2013).


- 783 24. Schwartz, C., *et al.* ILC2s regulate adaptive Th2 cell functions via PD-L1 checkpoint control. *J*
784 *Exp Med* **214**, 2507-2521 (2017).
- 785 25. Elsner, R.A. & Shlomchik, M.J. Germinal Center and Extrafollicular B Cell Responses in
786 Vaccination, Immunity, and Autoimmunity. *Immunity* **53**, 1136-1150 (2020).
- 787 26. Charles, N. Autoimmunity, IgE and FcεRI-bearing cells. *Curr Opin Immunol* **72**, 43-50
788 (2021).
- 789 27. Nakayama, T., *et al.* Th2 Cells in Health and Disease. *Annu Rev Immunol* **35**, 53-84 (2017).
- 790 28. Keegan, A.D., Leonard, W.J. & Zhu, J. Recent advances in understanding the role of IL-4
791 signaling. *Fac Rev* **10**, 71 (2021).
- 792 29. Paul, W.E. & Zhu, J. How are T(H)2-type immune responses initiated and amplified? *Nat Rev*
793 *Immunol* **10**, 225-235 (2010).
- 794 30. Soni, C., *et al.* Plasmacytoid Dendritic Cells and Type I Interferon Promote Extrafollicular B
795 Cell Responses to Extracellular Self-DNA. *Immunity* **52**, 1022-1038 e1027 (2020).
- 796 31. Sage, P.T., *et al.* Dendritic Cell PD-L1 Limits Autoimmunity and Follicular T Cell Differentiation
797 and Function. *J Immunol* **200**, 2592-2602 (2018).
- 798 32. Hagmann, B.R., Odermatt, A., Kaufmann, T., Dahinden, C.A. & Fux, M. Balance between IL-3
799 and type I interferons and their interrelationship with FasL dictates lifespan and effector
800 functions of human basophils. *Clin Exp Allergy* **47**, 71-84 (2017).
- 801 33. Palacios, R. Spontaneous production of interleukin 3 by T lymphocytes from autoimmune
802 MRL/MP-lpr/lpr mice. *Eur J Immunol* **14**, 599-605 (1984).
- 803 34. Renner, K., *et al.* IL-3 contributes to development of lupus nephritis in MRL/lpr mice. *Kidney*
804 *Int* **88**, 1088-1098 (2015).
- 805 35. Oon, S., *et al.* A potential association between IL-3 and type I and III interferons in systemic
806 lupus erythematosus. *Clin Transl Immunology* **8**, e01097 (2019).
- 807 36. Grzes, K.M., *et al.* Plasmacytoid dendritic cell activation is dependent on coordinated
808 expression of distinct amino acid transporters. *Immunity* **54**, 2514-2530 e2517 (2021).
- 809 37. Bonam, S.R., Chauvin, C., Mathew, M.J. & Bayry, J. IFN-gamma Induces PD-L1 Expression in
810 Primed Human Basophils. *Cells* **11**(2022).
- 811 38. Vitte, J., *et al.* A Granulocytic Signature Identifies COVID-19 and Its Severity. *J Infect Dis* **222**,
812 1985-1996 (2020).
- 813 39. Bonam, S.R., *et al.* SARS-CoV-2 Induces Cytokine Responses in Human Basophils. *Front*
814 *Immunol* **13**, 838448 (2022).
- 815 40. Lourda, M., *et al.* High-dimensional profiling reveals phenotypic heterogeneity and disease-
816 specific alterations of granulocytes in COVID-19. *Proc Natl Acad Sci U S A* **118**(2021).
- 817 41. Halfon, M., *et al.* CD62L on blood basophils: a first pre-treatment predictor of remission in
818 severe lupus nephritis. *Nephrol Dial Transplant* **36**, 2256-2262 (2021).
- 819 42. Rodriguez, L., *et al.* Systems-Level Immunomonitoring from Acute to Recovery Phase of
820 Severe COVID-19. *Cell Rep Med* **1**, 100078 (2020).
- 821 43. Wada, T., *et al.* Selective ablation of basophils in mice reveals their nonredundant role in
822 acquired immunity against ticks. *J Clin Invest* **120**, 2867-2875 (2010).
- 823 44. Chan, V.W., Meng, F., Soriano, P., DeFranco, A.L. & Lowell, C.A. Characterization of the B
824 lymphocyte populations in Lyn-deficient mice and the role of Lyn in signal initiation and
825 down-regulation. *Immunity* **7**, 69-81 (1997).
- 826 45. Voehringer, D., Liang, H.E. & Locksley, R.M. Homeostasis and effector function of
827 lymphopenia-induced "memory-like" T cells in constitutively T cell-depleted mice. *J Immunol*
828 **180**, 4742-4753 (2008).

829

830

831 **FIGURES**

832 **FIGURE 1**




833

834 **Figure 1: Human blood basophils from SLE patients overexpress PD-L1**

835

836 FIGURE 2




837

838 **Figure 2: Basophil-TFH functional relationship during lupus-like disease**

839


840 FIGURE 3



841
842
843

Figure 3: Basophils control TFH abilities to produce IL-21 and IL-4 in the lupus-like context

844 FIGURE 4




845

846 **Figure 4: A bidirectional crosstalk between basophils and CD4⁺ T cells promotes *ex vivo* TFH**
 847 **differentiation**

848

849 FIGURE 5
850




851

852 **Figure 5: PD-L1 controls the basophil-TFH functional relationship during lupus-like disease**

853

854 FIGURE 6




855

856 **Figure 6: Basophil-derived IL-4 controls T-dependent autoreactive antibody isotype switch in lupus-**
857 **like disease**

858

859 FIGURE 7




860

861 **Figure 7: Human basophils drive TFH cell and TFH2 cell differentiation through IL-4, IL-6 and PD-1**
 862 **dependent mechanisms *ex vivo***

863

864 **GRAPHICAL ABSTRACT**



865
866 Pathogenic accumulation of T follicular helper cells in lupus disease depends on PD-L1 and IL-4
867 expressing basophils.

868